• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

    2/14/23 12:30:13 PM ET
    $CYTH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CYTH alert in real time by email
    SC 13G/A 1 armistice-cyth123122a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    CYCLO THERAPEUTICS, INC.

    (Name of Issuer)

     

    Common Stock, par value $.0001 per share

    (Title of Class of Securities)

     

    23254X201

    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  23254X201
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,030,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    1,030,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,030,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    10.83%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  23254X201
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,030,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    1,030,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,030,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    10.83%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 23254X201
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    CYCLO THERAPEUTICS, INC.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    6714 NW 16th Street, Suite B

    Gainesville, Florida 32653

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common stock, par value 0.0001 per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    23254X201

     

    CUSIP No.  23254X201
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 23254X201
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of December 31, 2022:

    Armistice Capital, LLC - 1,030,000

    Steven Boyd - 1,030,000 

    (b) Percent of Class as of December 31, 2022:

    Armistice Capital, LLC - 10.83%

    Steven Boyd - 10.83% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 1,030,000

    Steven Boyd - 1,030,000 

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 1,030,000

    Steven Boyd - 1,030,000

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on 9,511,848 Shares outstanding as of December 29, 2022, as reported on the Issuer’s Form 424B3 filed with the Securities and Exchange Commission on January 3, 2023.

    Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 23254X201
     SCHEDULE 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 23254X201
     SCHEDULE 13G/A
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2023

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $CYTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CYTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Conkling William was granted 27,654 shares, increasing direct ownership by 55% to 77,884 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:45:25 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wong Vivien was granted 25,140 shares, increasing direct ownership by 63% to 64,853 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:45:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Cross Shawn was granted 28,597 shares, increasing direct ownership by 27% to 136,346 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:44:36 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CYTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

      NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics' shareholders representing approximately 22% of the combined company, based on the exchange ratio in the merger agreement between the parties determined to be 0.3525. Rafael also issued warrants to purchase shares of Rafael Class B common stock to certain holders of Cyclo warrants. Rafael Holdings has identified Trappsol® Cyclo™ as its lead clinical asset

      3/26/25 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

      The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo's lead clinical program Trappsol® Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025. "We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics (NASDAQ:CYTH) later this month and anticipate closing promptly post shareholder approvals. Upon closing, the Company's strategic focus will be on its lead clinical asset, T

      3/13/25 5:50:30 PM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

      First data in NPC1 on treatment in this age group over a period of 48 weeks At 24 weeks of the sub-study, 7 of 8 patients (87%) and at 48 weeks of the sub-study, 6 of 7 patients (86%) show stabilization or improvement in Clinical Global Impression – Change (CGI-C) Scale Data presented at the 21st Annual WORLDSymposium™ 2025 Company on track for topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ in H1 2025 Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with rare and

      2/7/25 8:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CYTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease

      – Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first physician in the U.S. to use cyclodextrins for treatment in NPC, compassionate use – Site activation ongoing and currently enrolling patients in pivotal Phase 3 study, TransportNPC™ – Data seen to-date provide support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with home-based intravenous infusions in NPC and demonstrate acceptable safety profile of Trappsol® Cyclo™ administered intravenously for more than 2 years Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-cha

      12/9/21 8:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CYTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

      SC 13G/A - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/14/24 2:44:54 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

      SC 13G/A - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/14/23 12:30:13 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cyclo Therapeutics Inc.

      SC 13G - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/10/23 4:28:56 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CYTH
    SEC Filings

    See more
    • SEC Form 15-12G filed by Cyclo Therapeutics Inc.

      15-12G - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      4/7/25 4:05:19 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      3/26/25 7:05:41 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      3/24/25 4:30:22 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CYTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group reiterated coverage on Cyclo Therapeutics with a new price target

      Maxim Group reiterated coverage of Cyclo Therapeutics with a rating of Buy and set a new price target of $25.00 from $12.00 previously

      2/10/21 8:07:06 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care